Suchergebnisse - "Anker, Stefan D"

PubPharm (5)

1

Empagliflozin in Black Versus White Patients With Heart Failure : Analysis of EMPEROR-Pooled

enthalten in: Circulation | 2023

von Verma, S. | Dhingra, N. | Butler, J. | +13

2

Empagliflozin in Heart Failure with a Preserved Ejection Fraction. Reply

enthalten in: The New England journal of medicine | 2022

von Anker, S. | Butler, J. | Packer, M.

CommentOn: N Engl J Med. 2022 May 26;386(21):e57. - PMID 35613030

3

Empagliflozin and Major Renal Outcomes in Heart Failure

enthalten in: The New England journal of medicine | 2021

von Packer, M. | Butler, J. | Zannad, F. | +9

CommentIn: N Engl J Med. 2021 Oct 14;385(16):1522-1524. - PMID 34449180

4

Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes : Insights From the EMPERIAL Trials

enthalten in: Circulation | 2021

von Anker, S. | Ponikowski, P. | Wanner, C. | +10

ErratumIn: Circulation. 2022 Feb 22;145(8):e641. - PMID 35188801

5

Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial

enthalten in: European journal of heart failure | 2021

von Packer, M. | Zannad, F. | Butler, J. | +8

1
[1]